Welcome to our dedicated page for Wave Life Scienc news (Ticker: WVE), a resource for investors and traders seeking the latest updates and insights on Wave Life Scienc stock.
Wave Life Sciences Ltd. develops RNA medicines as a clinical-stage biotechnology company, using its PRISM platform to design oligonucleotides across RNA editing, RNA interference and antisense silencing. Company news commonly centers on clinical and regulatory updates for investigational programs such as WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, and WVE-007, an INHBE GalNAc-siRNA evaluated for obesity and cardiometabolic disease biology.
Updates also cover financial results, corporate presentations, platform expansion, collaboration activity involving PRISM, and governance or capital-structure matters. Recurring scientific disclosures include trial data presentations, safety and tolerability findings, regulatory engagement, and pipeline work in liver, muscle and neurologic diseases.
Wave Life Sciences Ltd. (Nasdaq: WVE) has announced that Paul Bolno, MD, MBA, the President and CEO, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 11:30 a.m. ET. Investors can access a live webcast of the presentation on the company’s Investor Relations page. Wave Life Sciences focuses on developing life-changing genetic medicines for severe diseases using its proprietary PRISM platform, which allows for the precise design and production of stereopure oligonucleotides.
Wave Life Sciences (Nasdaq: WVE) announced an upcoming Analyst and Investor Research Webcast on August 25, 2020, focusing on advancements in its neurology pipeline, including preclinical data for the C9orf72 program targeting ALS and FTD. Presentations will be made by key executives, highlighting strategy updates and new data on the PRISM platform. The event aims to showcase Wave's commitment to developing life-changing genetic treatments for severe diseases.
Wave Life Sciences (Nasdaq: WVE) has announced it will host a live webcast and conference call on August 10, 2020, at 8:30 a.m. ET to discuss its second quarter 2020 financial results and provide a business update. Interested parties can access the call via the Investor Relations section of the Wave Life Sciences website. The company, focused on delivering genetic medicines, continues to develop therapies for genetically defined diseases utilizing its proprietary PRISMTM platform.
Wave Life Sciences (Nasdaq: WVE) announced that CEO Paul Bolno will present at the Jefferies 2020 Virtual Healthcare Conference on June 4, 2020, at 2:00 p.m. ET. The presentation will focus on the company's mission to develop life-changing genetic treatments using their proprietary PRISM platform. A live webcast will be available on the investor relations page of Wave's website, with a replay accessible for 90 days post-event. Wave Life Sciences is dedicated to addressing genetically defined diseases to improve patient futures.
Wave Life Sciences (Nasdaq: WVE) has appointed Dr. Kenneth Rhodes as Senior Vice President of Therapeutics Discovery. This newly established role will focus on advancing the company’s therapeutic pipeline, particularly in neurological diseases, utilizing the proprietary PRISM platform. Dr. Rhodes brings extensive experience from his previous roles at Yumanity Therapeutics and Biogen, emphasizing his capability to drive drug discovery initiatives. His appointment aligns with Wave's efforts to develop innovative treatments, including those for Huntington’s disease and related neurological conditions.
Wave Life Sciences (WVE) announced its Q1 2020 financial results, reporting a net loss of $47.5 million, up from $44.2 million in Q1 2019. Research and development expenses rose to $41.2 million, partially due to increased clinical activity related to Huntington's disease and a workforce reduction. The company maintains $120.9 million in cash, expecting to sustain operations through Q3 2021. Wave’s ongoing PRECISION-HD trials for Huntington's disease are progressing, and new data from its RNA-editing program demonstrate editing efficiencies of up to 50%.